Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes
Type2diabetes
About this trial
This is an interventional prevention trial for Type2diabetes focused on measuring Sulfonylureas
Eligibility Criteria
Inclusion Criteria: Age ≥ 45 years Type 2 diabetes (diagnosed on or before 12/31/2021) Current/active prescription for one or more SU medications Established care (≥2 visits) with UH primary care provider (PCP) since 2021 Exclusion Criteria: Type 1 diabetes PCP provides a reason why patient participation is inappropriate (e.g., known cost barriers without any alternatives, prior discussion with patient about alternatives, etc.) Patient unable or unwilling to have conversation with their PCP regarding SU Unable to provide informed consent
Sites / Locations
- University Hospitals Cleveland Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Prompt-sheet
Usual education
Question-prompt group patients will receive a simple prompt sheet with the questions with which they will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).